Susanne Malander

21 – 30 of 45

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/person/9dd29eb1-d06b-438e-8c67-c542fcace595?embed=1&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

2019
Mark Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden : a population-based study
Bagge, Ebba ; Beiron, Ulrica ; Malander, Susanne ^LU ; Rosenberg, Per and Åvall-Lundqvist, Elisabeth (2019) In Acta Oncologica 58(3). p.320-325
- Contribution to journal › Article
Mark Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
Del Campo, Josep M. ; Matulonis, Ursula A. ; Malander, Susanne ^LU ; Provencher, Diane ; Mahner, Sven ; Follana, Philippe ; Waters, Justin ; Berek, Jonathan S. ; Woie, Kathrine and Oza, Amit M. , et al. (2019) In Journal of Clinical Oncology 37(32). p.2968-2973
- Contribution to journal › Article
Mark Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method
Arildsen, Nicolai Skovbjerg ^LU ; Martin de la Fuente, Laura ^LU ; Måsbäck, Anna ^LU ; Malander, Susanne ^LU ; Forslund, Ola ^LU ; Kannisto, Päivi ^LU and Hedenfalk, Ingrid ^LU (2019) In Scientific Reports 9(1). p.1-8
- Contribution to journal › Article
2018
Mark Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA) : results from a double-blind, phase 3, randomised controlled trial
Oza, Amit M. ; Matulonis, Ursula A. ; Malander, Susanne ^LU ; Hudgens, Stacie ; Sehouli, Jalid ; del Campo, Josep M. ; Berton-Rigaud, Dominique ; Banerjee, Susana ; Scambia, Giovanni and Berek, Jonathan S. , et al. (2018) In The Lancet Oncology 19(8). p.1117-1125
- Contribution to journal › Article
Mark Claudin-4 Expression is Associated with Survival in Ovarian Cancer but Not with Chemotherapy Response
Martín De La Fuente, Laura ^LU ; Malander, Susanne ^LU ; Hartman, Linda ^LU ; Jönsson, Jenny Maria ^LU ; Ebbesson, Anna ^LU ; Nilbert, Mef ^LU ; Måsbäck, Anna ^LU and Hedenfalk, Ingrid ^LU (2018) In International Journal of Gynecological Pathology 37(2). p.101-109
- Contribution to journal › Article
Mark Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
Friedlander, Michael ; Rau, J. ; Lee, C. K. ; Meier, W. ; Lesoin, A. ; Kim, J. W. ; Poveda, A. ; Buck, M. ; Scambia, G. and Shimada, M. , et al. (2018) In Annals of Oncology 29(3). p.737-743
- Contribution to journal › Article
Mark Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS
Sajic, Tatjana ; Liu, Yansheng ; Arvaniti, Eirini ; Surinova, Silvia ; Williams, Evan G. ; Schiess, Ralph ; Hüttenhain, Ruth ; Sethi, Atul ; Pan, Sheng and Brentnall, Teresa A. , et al. (2018) In Cell Reports 23(9). p.5-2831
- Contribution to journal › Article
2017
Mark Claudin-4 expression is associated with progression free survival in ovarian cancer, but not with chemotherapy response
Martin de la Fuente, L. ^LU ; Malander, S. ^LU ; Hartman, L. ^LU ; Jönsson, J.-M. ^LU ; Ebbesson, A. ^LU ; Nilbert, M. ^LU ; Måsbäck, A. ^LU and Hedenfalk, I. ^LU (2017) In International Journal of Gynecological Pathology 37(2). p.101-109
- Contribution to journal › Article
Mark Involvement of chromatin remodeling genes and the Rho GTPases RhoB and CDC42 in ovarian clear cell carcinoma
Arildsen, Nicolai Skovbjerg ^LU ; Jönsson, Jenny Maria ^LU ; Bartuma, Katarina ^LU ; Ebbesson, Anna ^LU ; Westbom-Fremer, Sofia ; Måsbäck, Anna ^LU ; Malander, Susanne ^LU ; Nilbert, Mef ^LU and Hedenfalk, Ingrid A. ^LU (2017) In Frontiers in Oncology 7(MAY). p.1-11
- Contribution to journal › Article
2016
Mark Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Bois, Andreas du ; Kristensen, Gunnar ; Ray-Coquard, Isabelle ; Reuss, Alexander ; Pignata, Sandro ; Colombo, Nicoletta ; Denison, Ursula ; Vergote, Ignace ; Del Campo, Jose M and Ottevanger, Petronella , et al. (2016) In The Lancet Oncology 17(1). p.78-89
- Contribution to journal › Article